Ampolgen Pharmaceuticals, LLC. is in engaged in research and development of gene targeted therapies. Ampolgens current efforts focus on Sodium Phenylbutyrate (PB) and related compounds. Ampolgen was established in December of 2003, in order to engage in research, manufacturing, marketing, promotion, and sale of certain compounds which are known to effect expression of genes.
Our manufacturing facility, as well as our Research and Development unit, are located in Stafford, Texas, with Sales and Administrative office building located in neighboring West Houston,Texas.
The main efforts are concentrated on initiation, distribution and marketing of Sodium Phenylbutyrate as adjunctive therapy in the chronic management of patients with urea cycle disorder.